Vicor Technologies Announces Addition to Scientific Advisory Board

Vicor Technologies, Inc. (OTCBB: VCRT), focused on the commercialization of the PD2i Cardiac Analyzer, a patented device utilized in the risk stratification of patients for Sudden Cardiac Death (SCD), announces the addition of Edward F. Lundy, M.D., Ph.D. to its Scientific Advisory Board.

Edward F. Lundy, M.D., Ph.D. is Chief of Cardiothoracic Surgery at the Active International Cardiovascular Institute at Good Samaritan Hospital in Suffern, New York. In addition to his M.D. from the University of Michigan, Dr. Lundy also received a Ph.D. from that institution in Physiology with a primary focus on altered-state physiologies such as hibernation.

Commenting on the appointment, Mr. Fater stated, "We are delighted to have an individual like Dr. Lundy join our Scientific Advisory Board. His background in both cardiology and altered-state physiologies provides him with a unique perspective with which to assist Vicor in the expansion of several of our platform technologies. He joins other distinguished physicians and scientists and we are delighted to have him on the Vicor team."

Dr. Lundy joins the other members of Vicor's Scientific Advisory Board which include:

--  Edward Wiesmeier, M.D., Clinical Professor, Obstetrics & Gynecology,
    University of California-San Diego, serves as Chairperson of the Board, and
    recently retired as Assistant Vice Chancellor of the UCLA School of
    Medicine.

--  Mark E. Josephson, M.D., Chief of Cardiology at Beth Israel Deaconess
    Medical Center, a major patient care, research and teaching affiliate of
    Harvard Medical School and the author of Clinical Cardiac
    Electrophysiology, the fundamental textbook in the field.

--  Hein J. J. Wellens, M.D., Professor and Chairman of the Department of
    Cardiology at Academisch Ziekenhuis Maastricht in Amsterdam, the
    Netherlands.  He is a Director of the Interuniversity Cardiology Institute
    of the Netherlands and is a member of the Netherlands Academy of Arts and
    Sciences.  He also has an appointment of visiting lecturer at Harvard
    Medical School.

--  Richard M. Luceri, M.D., F.A.C.C., recently retired Director of the
    Interventional Arrhythmia Center at Holy Cross Hospital, Fort Lauderdale,
    FL, as well as a clinical investigator in the MADIT II (MultiCenter
    Automatic Defibrillator Implantation Trial) and author SCDHeFT (Sudden
    Cardiac Death Heart Failure Trial).

--  Hank Lubin, M.D., a practicing physician with Hightstown Medical
    Associates, PA, (formerly affiliated with the University of Pennsylvania
    Health System) and currently a Clinical Associate Professor at The
    University of Pennsylvania School of Medicine.

--  Jules T. Mitchel, M.B.A., Ph.D., the Founder of Target Health, Inc., a
    full-service contract research organization supporting all aspects of
    pharmaceutical drug and device development.

--  Frank S. Caruso, Ph.D., the Founder of two successful start-up
    pharmaceutical companies (Algos Pharmaceutical Corporation and Roberts
    Pharmaceutical Corporation). He has more than 30 years experience directing
    worldwide clinical/pharmacological research and biological evaluation
    programs involving licensing and drug development research planning.

--  David Fertel, D.O., a practicing Board Certified Thoracic and
    Cardiovascular surgeon in Michigan.

    

About Sudden Cardiac Death (SCD)

SCD (the leading killer in the U.S. with over 500,000 annual deaths) is a fatal arrhythmic event and is different than a heart attack. A heart attack is analogous to a plumbing problem, where the blood supply to a part of the heart is choked off, leading to the death of that portion of the heart muscle. SCD is theorized to be caused by a breakdown of the normal neurological communication pattern between the heart and brain, more like an electrical problem, which can lead to a rapid, life threatening heart rhythm that is usually fatal within minutes, if untreated. It is swift, unexpected, and often has no advance warning or symptoms.

About Vicor Technologies, Inc.

Vicor Technologies' (OTCBB: VCRT) medical device, the PD2i Cardiac Analyzer, is based on a patented, proprietary algorithm. Vicor believes the PD2i Cardiac Analyzer accurately risk stratifies patients who are at high or low risk of suffering a fatal arrhythmic event or SCD within a six-month time frame.

Vicor's PD2i Cardiac Analyzer addresses a significant health care issue involving a patient cohort of at least 12,000,000 patients. This patient cohort is composed of the MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II)/SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) patient population. Many in this patient cohort may need an ICD (Implantable Cardioverter Defibrillator) as life saving therapy. However, recent registry studies have noted that over 70% of implanted ICD's never have an appropriate firing. This over-implantation has led to a substantial and unnecessary medical cost burden. Over-implantation of this patient cohort also puts patients at risk because of the complications that can accompany implantation surgery. There is also the risk of not identifying patients who need this life-saving therapy because current criteria do not provide physicians the ability to accurately risk stratify their patients.

The PD2i Cardiac Analyzer contains the patented PD2i algorithm which provides a method for evaluating electrophysiological potentials with a high sensitivity and high specificity used to predict future pathological events i.e. fatal cardiac arrhythmias. The PD2i algorithm detects deterministic, low-dimensional excursions in nonstationary heartbeat intervals. The PD2i algorithm uses an analytic measure that is deterministic and nonlinear. It is based on caused variation in data; does not require data stationarity and actually tracks nonstationary changes in the data. It is sensitive to chaotic as well as nonchaotic, linear data.

The mission of the Vicor drug discovery platform is to focus on the pre-clinical and early clinical development of specific naturally occurring peptides and proteins derived from "state-dependent" physiologies that will revolutionize the treatment of an array of human diseases.

For more information visit the Vicor Technologies web site www.vicortech.com.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to continue to receive financing sufficient to complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and changes in laws and regulations. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.